Either ‘private mutations’ or commonly shared tumor – associated antigens, i.e. NY-ESO-1, mesothelin, or common infectious pathogen antigens, e.g. EBV or CMV, provide a ‘recognition fingerprint’ to follow the immune response pattern in immunological therapies. The gene discussed is MSLN; the disease is neoplasm.